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ABSTRACT 
Background: Reactive oxygen species (ROSs) play an important role in the 
pathogenesis of asthma, and oxidative stress contributes to the initiation and 
worsening of inflammatory respiratory disorders (eg, asthma). Thus, antioxi- 
dant drugs may have a role in reducing or preventing damage in asthma. 
Objective: The aim of the study was to investigate the antioxidant effect of 
zafirlukast, a leukotriene receptor antagonist, in asthma. 
Methods: This prospective, controlled, in vitro study was conducted at King 
Khalid University Hospital, Riyadh, Saudi Arabia. The generation of ROSs by 
polymorphonuclear neutrophil leukocytes (PMNs) in patients with mild to mod- 
erate asthma (forced expiratory volume in 1 second [FEV1], >70% of the pre- 
dicted value) and healthy volunteers was assessed using chemiluminescence 
(CL) with phorbol 12-myristate 13-acetate (PMA) and opsonized zymosan (OPZ) 
in the presence of different concentrations of zafirlukast (1.25-60 pg/mL). The 
xanthine/xanthine oxidase (X-XOD) reaction was used to test the scavenging 
effect of the drug. 
Results: Six asthmatic patients (4 women, 2 men; mean age, 30.8 years; mean 
FEV 1, 82.5% of the predicted value) and 8 healthy volunteers (4 women, 4 men; 
mean age, 28.8 years) were nrolled. A dose-dependent inhibition of the CL 
response was observed in both groups. However, patients with asthma required 
higher concentrations of zafirlukast o achieve an inhibitory effect similar to 
that in healthy controls. This difference was significant at concentrations of 20 to 
60 pg/mL (all, P ~ 0.05). When PMNs were challenged with OPZ, inhibition was 
also dose dependent in controls at all concentrations (all, P _< 0.05), but the 
inhibitory effect was not significant in the asthmatic patients at any concentra- 
tion. The difference in the inhibitory effect between the 2 groups was significant 
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at 30, 40, and 60 IJg/mL (P < 0.02, <0.01, and <0.01, respectively). The mean 
(SEM) viability of the PMNs in the healthy controls was significantly affected 
only at the highest concentration compared with the control saline dose (86.5% 
[5.8%] vs 97.0% [8.%]; P < 0.05). No scavenging effect of zafirlukast was found 
using the X-XOD system. Incubating PMA-stimulated cells with zafirlukast (5 
and 10 IJg/mL) for 10 minutes to 1 hour significantly increased the inhibitory 
effect of the drug by 15% to 46% (all, P < 0.001). When zafirlukast was tested for 
reversibility of its inhibitory effect on ROS production, its action was found 
to be irreversible at a concentration of 30 IJg/mL (P < 0.001) and partially re- 
versible at 60 IJg/mL compared with the baseline saline control. 
Conclusions: Zafirlukast inhibited ROS generation by PMNs in a dose- 
dependent manner in asthmatic patients and healthy subjects. However, asth- 
matic patients required much higher concentrations compared with controls. 
The incubation of the stimulated cells with zafirlukast increased the inhibitory 
effect. This finding suggests that the therapeutic effect of zafirlukast in asthma 
may be in part related to its antioxidant action. (Curt Ther Res Clin Exp. 2005; 
66:279-293) Copyright © 2005 Excerpta Medica, Inc. 
Key words: zafirlukast, polymorphonuclear leukocytes, asthmatic patients, 
reactive oxygen species, healthy volunteers, chemiluminescence. 
INTRODUCTION 
Bronchial asthma, which is most accurately thought of as a syndrome con- 
sisting of a common pathway of injury from a variety of insults, can be medi- 
ated through multiple mechanisms of inflammation and repair. 1 Neutrophils, 
eosinophils, and other cells involved in the inflammatory response can gener- 
ate large amounts of free radicals, which can be measured in exhaled gas. 
Hanazawa et al 2 reported a significant increase in exhaled free radical metabo- 
lites in patients with mild asthma who were not treated with corticosteroids. 
Neutrophils with altered function have been found in blood from asthmatic 
patients before and after antigen challenge. These alterations include de- 
creased density, increased complement receptor type 3 expression, altered 
response to regulating agents, generation of oxygen metabolites, and increased 
leukotriene (LT) production and secretion. 3 
Stimulation of human leukocytes by various agents, including phagocytic 
stimuli, results in the synthesis of the bioactive arachidonic acid-derived LTs. 
The major arachidonic acid-derived metabolites synthesized by polymorpho- 
nuclear neutrophil leukocytes (PMNs) are LTs A4 and B4. The free arachidonic 
acid generated by phospholipase A 2 can be released to the extracellular com- 
partment, where it is utilized in LT biosynthesis by agonist-stimulated PMNs. In 
pathologic situations, such as bronchial asthma, the efficient utilization of accu- 
mulated arachidonic acid results in increased production of LTs. 4 
The cysteinyl LTs C4 and D4 (cys LTC4 and LTD4) have been found to be 
potent bronchoconstrictors in guinea pig airways in vitro and in vivo and to 
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cause isolated human bronchi to contract. 5 LTC4, LTD4, and LTE4 have been 
found to cause tissue edema. ~It has also been observed that LTC4 and LTD4 
may stimulate mucus secretion in isolated animal Tand human s airways. More 
recently, additional effects with potential relevance to the role of cys LTs in 
asthma nd pulmonary inflammation have been reported. Increased infiltration 
of eosinophils into the airway mucosa of asthmatic patients have been ob- 
served after inhalation of LTE4 and LTD4. 9 Urinary excretion of LTE4 has been 
found to be increased uring an acute attack of asthma 1° and after challenge 
with allergens, exercise, or aspirin ingestion, zzIn a guinea pig trachealis model, 
Weiss and Bellino z2 found a statistical correlation between exogenous LTD4 and 
reactive oxygen species (ROS) production that resulted in acquired hyperreac- 
tivity to histamine in airway smooth muscle. This effect was blocked by an LT 
antagonist (FPL 55712) and, unexpectedly, bysuperoxide dismutase, suggesting 
that LTD4 stimulated the release of ROSs, which were mainly derived from 
PMNs and/or mast cells. 
Pharmacotherapy for asthma, which has remained essentially unchanged 
over the past 3 decades, consists of glucocorticoids, 132-agonists, and theophyl- 
line. Based on the involvement of LTs in the production of bronchoconstriction, 
antileukotrienes, and in particular the LT receptor antagonists, offer an impor- 
tant alternative class of drug therapy for asthma. 13 These drugs have some 
advantages over bronchodilators u ed to treat bronchial asthma because the 
disease is associated with an inflammatory reaction, z4 Zafirlukast is a potent 
and selective cys LT receptor antagonist that has been approved by the US Food 
and Drug Administration for the prophylactic treatment of asthma in patients 
aged ~12 years. 15 The drug causes significant attenuation of the early and late 
responses to inhalational ntigens and reduces the bronchial hyperresponsive- 
ness to histamine that typically accompanies antigen inhalation. IG Zafirlukast 
complements he anti-inflammatory effects of corticosteroids and has been 
studied in combination with corticosteroids a  an alternative to high-dose in- 
halational corticosteroids. IT Despite these actions of zafirlukast, PubMed and 
Ovid searches (key words: asthma, reactive oxygen species, and zafirlukast; 
years: 1996-2005) revealed that the effect of zafirlukast on the function of PMNs 
isolated from asthmatic patients has not yet been studied. 
The aim of this in vitro study was to investigate whether zafirlukast affects 
the production of ROSs from PMNs obtained from asthmatic patients and 
healthy subjects. 
PATIENTS AND METHODS 
Inclusion and Exclusion Criteria 
Asthmatic patients and healthy volunteers aged 20 to 45 years were recruited 
for this prospective, controlled, in vitro study. The volunteers were recruited 
from a pool of blood donors at King Khalid University Hospital, Riyadh, Saudi 
Arabia. Patients were eligible if they were clinically stable and known to have 
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mild to moderate asthma, defined as forced expiratory volume in 1 second 
(FEV1) >70% of the predicted value; and reversible airway disease, defined as a 
~15% increase in FEV 1 after bronchodilator inhalation. Asthmatic patients receiv- 
ing continuous maintenance therapy were excluded. Subjects were excluded if
they had a history of recent infection, had any other medical problems (deter- 
mined by subject interview), or were smokers. Patients were instructed not to 
use any medications for at least 24 hours before the collection of blood samples. 
All individuals provided oral informed consent to participate inthe study. The 
study was approved by the ethics committee of King Khalid University Hospital. 
Peripheral venous blood was drawn from all study participants and trans- 
ferred to heparinized tubes. 
Material Preparation 
Polymorphonuclear Neutrophil Leukocyte Separation 
PMNs were separated using a neutrophil isolation medium (Cardinal Asso- 
ciates Inc., Santa Fe, New Mexico). Five to 7 mL of heparinized blood was layered 
over 4 mL of the neutrophil solation medium in a 15-mL tube, which was cen- 
trifuged (Heraeus-Christ GmbH, Osterode, Germany) at 400g for 30 minutes at 
room temperature. The leukocyte-rich plasma was removed using a Pasteur 
pipette and transferred to a 15-mL conical centrifuge tube. The tube was filled 
with phosphate-buffered saline (PBS) and centrifuged at 350g for 10 minutes at 
room temperature. The residual erythrocytes were lysed using 2 mL of lysing 
buffer (E-lyse, Cardinal Associates Inc.), vortexed to resuspend the pellets, and 
then centrifuged at 250g for 10 minutes at room temperature. The supernatant 
was discarded and the sediment was suspended in 1 mL of 5% fetal calf serum. 
The cells were counted and adjusted to a concentration of 5 x 10 ~ cells/mL. 
Reagents 
Various stimulants made it possible to define the signal transduction path- 
ways and the involvement ofother cellular functions, such as phagocytosis and 
degranulation. Clinically, phorbol 12-myristate 13-acetate (PMA) was used to 
monitor cellular defects, and opsonized zymosan (OPZ) was used to detect de- 
fects in immunologic functions. 1~ 
Phosphate-Buffered Saline Solution 
PBS was dissolved in distilled water to the following concentrations: sodium 
chloride 0.14 M, potassium chloride 2.7 mM, disodium hydrogen orthophos- 
phate 12 mM, potassium dihydrogen phosphate 1.5 mM, calcium chloride 0.9 mM, 
and magnesium chloride 0.49 mM. 
Luminol 
Luminol (no. 1243-216, LKB-WalIac Company, Turku, Finland) was dissolved 
in dimethyl sulfoxide to give a concentration of 1.77 mg/mL, which was further 
diluted in PBS to 17.7 pg/mL prior to use. 
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Phorhol Myristate Acetate Solution 
PMA was dissolved in dimethyl sulfoxide to give a stock solution of 2 mg/mL. 
The solution was stored at -20°C until use. It was further diluted with PBS to 
20 ng/mL prior to use. 
Opsonization of Zymosan 
Particulate zymosan was washed twice and resuspended in PBS, and its 
concentration was adjusted to 12.5 mg/mL. To opsonize the drug, 900 DL of 
zymosan suspension was incubated at 37°C for 30 minutes with 100 pL of autol- 
ogous human serum obtained from healthy individuals. It was then washed with 
PBS and resuspended in PBS to give a final concentration of 1.25 mg/mL. 
Zafirlukast 
To each 2 mg of zafirlukast powder 6 pL of 1N sodium hydroxide was added 
until the mixture appeared pasty. Then 100 pL of polyethylene glycol (molecu- 
lar weight, 400) was added. This pastelike material was warmed at ~50°C until 
a clear solution was obtained. PBS (pH 7.4) was added (in increments of 200 pL 
to avoid precipitation) to make 2 mL of solution. The stock solution (1 mg/1 mL) 
was further diluted to the required concentration (range, 1.25-60 pg/mL). For 
example, to prepare the 60-pg/mL concentration, 60 pL of the stock solution, 
which contained 60 pg, was transferred to a tube, and 940 pL of PBS was added 
to reach the required volume (1 mL). 
Assessments 
Chemiluminescent Assay 
The chemiluminescent assay was performed using a luminometer (model 
1251, LKB-WalIac Company), which is a bench-top, computer<ontrolled instru- 
ment hat monitors phagocytic events in real time. The luminometer was coupled 
with a monitor and a printer. Disposable polystyrene cuvettes and micropipettes 
with disposable tips for dispensing 100- to 1000-pL volumes were used. 
The effect of zafirlukast on the generation of ROSs, as assessed using peak 
chemiluminescence (CL) as described previously, 1~ was determined by the 
addition of different concentrations of the drug to isolated PMNs that were 
stimulated by PMA or OPZ. 
Various reagents were placed into quadruplet cuvettes using a pipette. The 
first tube was the baseline, containing 700 pL PBS, 200 pL luminol, and 100 pL 
PMNs. The second was the control tube containing 500 pL PBS, 200 pL luminol, 
100 pL PMNs, and 200 pL of a stimulant (PMA or OPZ). The third and fourth 
tubes contained 400 pL PBS, 200 pL luminol, 100 pL PMNs, 100 pL zafirlukast, 
and 200 pL of a stimulant (PMA or OPZ). The cuvette contents were mixed gent- 
ly, and the light emission was recorded in millivolts. The assay temperature was 
maintained at 37°C. Each sample was measured over a period of 30 minutes. 
Using a computer, the results were plotted on a graph, with the y-axis represent- 
ing the light intensity (mV) and the x-axis representing the time (minutes). 
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Cell-Free Xanthine/Xanthine Oxidase System 
The xanthine/xanthine oxidase (X-XOD) reaction was used to generate 
superoxide, as described by Gionchetti et al. 2° The catalyzed reaction of XOD 
on xanthine was induced by incubating 0.05 U/mL of XOD in PBS (pH 7.4) con- 
taining 0.1 mmol/L EDTA, 50 mmol/L xanthine, and 10 -4 mol/L luminol. The dif- 
ferent concentrations of the drug were incubated with xanthine and luminol 
for 5 minutes before XOD was added. Superoxide was measured using CL. 
Polymorphonuclear Leukocyte Viability 
Using concentrations of 30 and 60 IJg/mL, the cytotoxicity of zafirlukast on 
PMNs was assessed in healthy controls. PMNs were incubated in zafirlukast for 
10 minutes to 1 hour at 37°C. The percentage ofviable cells was estimated using 
the trypan blue (0.2% w/v) exclusion test (ie, the cells that absorbed the dye 
were considered nonviable). 
Effect of Zafirlukast Incubation on Polymorphonuclear Neutrophil Leukocytes 
The effect of zafirlukast 5 and 10 Dg on ROS generation was tested at 0, 10, 
30, and 60 minutes of zafirlukast incubation at 37°C. 
Reversibility of Zaflrlukast Action 
To investigate whether zafirlukast would have a permanent effect on PMNs, 
zafirlukast 30 and 60 Dg were incubated for 45 minutes with isolated PMNs and 
washed several times with PBS. The CL of unwashed and washed samples was 
recorded in the presence or absence of zafirlukast. 
Statistical Analysis 
The nonparametric Mann-Whitney U test was used to compare results from 
the asthmatic patients with those from healthy controls. A P value <0.05 was 
considered statistically significant. A power analysis was not performed. All 
data are presented as mean (SEM) of the peak CL. 
RESULTS 
Study Population 
Six asthmatic patients (4 women, 2 men; mean age, 30.8 years; mean FEVp 
82.5% of the predicted value) and 8 healthy volunteers (4 women, 4 men; mean 
age, 28.8 years) were recruited for the study. 
Polymorphonudear Neutrophil Leukocyte Chemiluminescence Response 
When PMNs were challenged with PMA in the presence of increasing concen- 
trations of zafirlukast (1.25-60 IJg/mL), significant dose-dependent i hibition of 
CL response was observed with concentrations of 5 to 60 Dg/mL in asthmatic 
patients (all, P___ 0.05) and with concentrations of 2.5 to 60 IJg/mL in healthy con- 
trols (all, P < 0.001) compared with the baseline saline control dose (Table I). 
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Table I. Effects of zafirlukast on phorbol myristate acetate-induced peak chemilumines- 
cence responses of polymorphonuclear neutrophil leukocytes isolated from 
patients with mild to moderate asthma and healthy volunteers (control group). 
Peak Chemiluminescence Response, Mean (SEM), mV 
Zafirlukast 
Concentration, Asthmatic Patients Healthy Volunteers 
IJg/mL (n = 6) (n = 8) P* 
0 t 431 .S (57.6) 474.2 (31 .S) 1.00 
1.25 441.9 (58.2) 441 .S (31.0) 0.70 
2.:5 424.8 (6:5.3) 371.3 (28.6)* 0.07 
:5 323.8 (39.9)§ 2:54.1 (21.7)* 0.07 
10 270.3 (34.6)* 1 68.9 (1:5.2) I 0.09 
20 230.4 (2:5.7)* 1 42.8 (11.:5)* 0.0:5 
30 203.8 (23.:5)* 1 32.4 (10.1)* 0.0:5 
40 1 6:5.2 (28.7)* 97.7 (8.:5)* 0.01 
60 139.9 (41.4)* :5:5.:5 (3.8)* 0.006 
*Between-group differences. 
tSaline (baseline control). 
~P < 0.001 versus baseline control. 
~P < 0.05 versus baseline control. 
The inhibitory effect was significantly different between the 2 groups at 20 to 
60 pg/mL (all, P ~ 0.05), with the highest inhibitory effect achieved with zafir- 
lukast 60 pg/mL. The concentrations of zafirlukast required to inhibit peak CL 
by 50% in patients and controls were 25 and 5 pg/mL, respectively (Figure 1). 
When OPZ was used as a stimulant, the inhibition was dose-dependent i  
healthy controls at all concentrations (all, P ~ 0.05), but the inhibitory effect 
was nonsignificant in the asthmatic group at all concentrations. The difference 
in the inhibitory effect between the 2 groups was significant at 30, 40, and 60 pg/mL 
(P < 0.02, <0.01, and <0.01, respectively) (Table II and Figure 2). 
Polymorphonuclear Neutrophil Leukocyte Viability 
We found significant mean (SEM) viability with the highest concentration of 
zafirlukast (60 pg/mL) compared with the baseline saline control dose (86.5% 
[5.8%] vs 97.0% [8.0%]; P < 0.05) (Table III). 
Cell-Free System 
Zafirlukast had no inhibitory effect on superoxide generation using the X-XOD 
reaction. 
Effect of Incubation of Zafirlukast on the Chemiluminescence 
Response of Isolated Polymorphonuclear Neutrophil Leukocytes 
Ten-minute incubation of PMA-stimulated cells with zafirlukast increased the 
inhibitory effect of the drug by 15% for the 5- and 10-pg/mL concentrations in
285 
CURRENT THERAPEUTIC RESEARCH 
600 - 
-M- Asthmatic patients (n = 6) 
--o- Healthy volunteers (n = 8) 
500 - £ 
E 





0 I I I '~:  I ,~t I I I I I 
01 1.25 2.5 5 10 20 30 40 60 
Zafirlukast Concentration (pg/mL) 
Figure 1. Effects of zafirlukast on the phorbol myristate acetate-induced chemilumi- 
nescence (CL) responses of polymorphonuclear neutrophil leukocytes iso- 
lated from patients with mild to moderate asthma and healthy volunteers 
(control group). *P < 0.001 versus baseline control; tp < 0.05 versus base- 
line control; *P = 0.05 versus control group; §P = 0.01 versus control group; 
lip = 0.006 versus control group; 1Saline (baseline control). 
Table II. Effects of zafirlukast on opsonized zymosan acetate-induced peak chemilumi- 
nescence responses of polymorphonuclear neutrophil leukocytes isolated from 
patients with mild to moderate asthma and healthy volu nteers (control group). 
Zafi rl u kast 
Concentration, 
IJg/mL 
Peak Chemiluminescence Response, Mean (SEM), mV 
Asthmatic Patients Healthy Volunteers 










881.8 (1 70.8) 587.5 (33.4) 0.81 
998.0 (1 48.1 ) 51 9.9 (32.8)* 0.26 
1024.8 (157.5) 506.5 (32.0)* 0.17 
859.6 (1 61.4) 493.7 (31.5)§ 0.1 7 
829.8 (1 69.5) 482.7 (31.0)§ 0.19 
811.7 (155.6) 438.8 (30.7)§ 0.11 
777.1 (I 60.1) 330.1 (29.0)§ 0.02 
748.6 (1 48.5) 201.5 (20.3)§ 0.01 
821.5 (119.2) 78.3 (6.5)§ 0.01 
*Between-group differences. 
tSaline (baseline control). 
~P < 0.0S versus baseline control. 
~P < 0.001 versus baseline control. 
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Zafirlukast Concentration (pg/mL) 
Effects of zafirlukast on the opsonized zymosan-induced chemiluminescence 
(CL) responses of polymorphonuclear neutrophil leukocytes isolated from 
patients with mild to moderate asthma and healthy volunteers (control 
group). *P < 0.05 versus baseline control; tp < 0.001 versus baseline control; 
*P = 0.02 versus control group; §P = 0.01 versus control group; IISaline (base- 
line control). 
Table III. Effects of zafirlukast on the viability of polymorpho- 
nuclear leukocytes isolated from healthy volunteers 




IJg/mL Viability, % 
O* 97.0 (8.0) 
30 9s.2 (6.7) 
60 86.s (s.8) 
*Saline (baseline control). 
tp < 0.05 versus baseline control. 
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healthy controls (both, P < 0.001). Incubation for 30 minutes resulted in an increase 
in the inhibition of 30% to 35% for both concentrations, and the 1-hour incubation 
increased the inhibitory effect of the drug by 34% to 46% (all, P < 0.001) (Table IV). 
Reversibility of the Inhibitory Effect of Zafirlukast 
lrreversibility of zafirlukast action was significant at 30 IJg/mL compared with 
baseline saline control (P < 0.001). Inhibition of the CL response remained almost 
unchanged (before washing, 70%; after washing, 65%). The action of a higher 
concentration (60 IJg/mL) was found to be partially irreversible before and after 
cell washing (86.0% and 54.6% inhibition, respectively) (Table V). 
DISCUSSION 
The results of the present study suggest an inhibitory effect of the cys LT receptor 
antagonist zafirlukast on ROS production by PMNs. This effect was more evident 
in healthy volunteers compared with asthmatic patients. To explore the associ- 
ation between LTs and ROS production, we used the luminol-dependent CL 
method to examine the effect of zafirlukast on the capacity of isolated PMNs to 
generate ROSs. The results obtained in healthy controls howed that, without 
incubation, zafirlukast was associated with significant inhibition of both PMA- 
and OPZ-stimulated ROS generation in a concentration-dependent manner. In 
contrast, Braga et a121 found that the incubation of different concentrations of 
zafirlukast with PMNs for only 10 minutes did not have a significant effect on 
the respiratory bursts induced by different stimuli (ie, Candida albicans and 
zymosan). However, prolonging the incubation for 1 hour resulted in a reduc- 
tion in the respiratory bursts of PMNs in healthy volunteers at a concentration 
of 5 x 10 -~ M (2.88 IJg/mL) when they were stimulated with PMA but not zymosan. 
The difference between our findings and those of Braga et a121 is probably 
related to the different concentrations of the drug used. In our study, the con- 
centrations used ranged from 1.25 to 60 pg/mL, whereas the concentrations 
Table IV. Effects of incubation with zafirlukast on phorbol myristate acetate-induced 
peak chemiluminescence responses of polymorphonuclear neutrophil leu- 
kocytes isolated from healthy volunteers (control group; n = 6). 
Zafirlukast Peak Chemiluminescence Response, Mean (SEM), mV 
Concentration, 
~g/mL 0 Min 10 Min 30 Min 60 Min 
O* 474.S (31.S) 429.3 (30.2) 3S2.4 (28.6) 289.1 (25.6) 
5 254.4 (21.7) t 1 60.6 (14.5) t 61.7 (2.5) t 20.9 (1.6) t 
10 1 69.0 (15.0) t 88.5 (7.3) t 1 9.9 (1.2) t 5.8 (0.7) t 
*Saline (baseline control). 
tp < 0.001 versus baseline control. 
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Table V. Reversibility of the effects of zafirlukast on phorbol myristate acetate- 
induced peak chemiluminescence responses of polymorphonuclear neu- 
trophil leukocytes isolated from healthy volunteers (control group; n = 6). 
Zafi rl u kast 
Concentration, 
pg/mL 
Peak Chemiluminescence Response, Mean (SEM), mV 




450.5 (31.0) 390.6 (29.8) 0.007 
135.2 (3.5) :1: 135.6 (3.7) :1: 0.87 
63.1 (4.1)* 1 77.2 (2.2)* 0.23 
*Unwashed versus washed. 
fSaline (baseline control). 
~P < 0.001 versus baseline control. 
used in the study by Braga et a121 ranged from 5 x 10 -9 to 5 x 10 -s M (0.0028- 
2.88 pg/mL), which were less than the therapeutic plasma drug concentration 
(0.25-10 IJg/mL). 15 In the present study, significant inhibition of ROS production 
was observed at the lowest concentration of the drug used, without any incu- 
bation. However, incubation of different concentrations of zafirlukast for up to 
1 hour was associated with an increase in the inhibitory effect of the drug, a 
finding that is consistent with those of Braga et al. 21 
In the present study, zafirlukast was associated with more inhibition of 
PMA-stimulated ROS production compared with that induced by OPZ. This 
finding agrees with that of Della Bianca et al, 22 who concluded that, depend- 
ing on the receptor or combination of receptors activated, different signal 
transduction pathways might be involved in phagocytosis and the associated 
respiratory burst. Another study showed that, after activation of PMNs, sig- 
nificant amounts of LTC4 were released. 23In addition, Raulf and Konig 24 
found that stimulation of human PMNs with OPZ resulted in time- and dose- 
dependent releases of LTB4 and LTC4. On the other hand, priming of PMNs 
with PMA has been shown to increase 5-1ipoxygenase kinase activity by 
translocation of 5-1ipoxygenase to the nucleus and increases its capacity for 
phosphorylation. 25 Therefore, signal transduction pathways involved in the 
stimulation of PMA receptors will result in high 5-1ipoxygenase production. 25
In the present study, the PMNs of asthmatic patients were found to be more 
resistant o inhibition when stimulated with PMA compared with those of 
controls. A possible cause of this difference is that the PMNs of asthmatic 
patients might have increased production of ROSs 2G and LTs 3 compared with 
controls, and thus the asthmatic patients required higher doses of the drug 
to overcome the exaggerated response of PMNs to the stimulator. Another 
possible mechanism is that increased production of leukotrienes in asthmatic 
patients led to a decrease in their receptors on PMNs, which decreased the 
response of the cells to the drug. 
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In the present study, no statistically significant inhibition of PMNs was found 
after OPZ stimulation in asthmatic patients, whereas tatistically significant 
inhibition was found in the controls. This difference could be due to the increase 
in complement receptor type 3, which is involved in clearing OPZ on PMNs in 
asthmatic patients. 3,27 
Cys LTs have 2 classes of G-protein-coupled receptors: cys LT1R and cys 
LT2R. 28 Both receptors are expressed on eosinophils and mast cells, whereas 
cys LT1R is expressed predominately onsmooth muscle cells, lung fibroblasts, 
and neutrophils. 29It has been suggested that LTD4 receptors on human 
bronchial smooth muscle are coupled to phospholipase D activation, yielding 
diacylglycerol and resulting in the activation of phosphokinase C. 3° Therefore, 
LTD4-induced contraction, at least in part, is independent of increases in Ca 2÷ 
release. It has also been suggested that during an asthmatic attack, eosinophils, 
macrophages, and mast cells produce cys LTs in the lung, which might activate 
cys LT1R in bronchial smooth muscle, leading to bronchoconstriction. 31 Activa- 
tion of neutrophils leads to the generation of cys LTs32; both LTC4 28 and LTD4 33 
can interact with cys LT1R on neutrophils and induce their activation. There- 
fore, cys LTs might act in an autocrine and paracrine manner on cys LT1Rs pres- 
ent on granulocyte membranes. 31 
Synthetic LTC4 binds to human PMN receptors with rapid saturation, and its 
action has been found to be 90% reversible. 34The features of these receptors 
are compatible with their role in mediating uptake and metabolism of LTC4 by 
PMNs. 34 In a study of the metabolism of cys LTs, Raulf et a135 found that, in con- 
trast to LT release, PMA and OPZ were more potent in activating the metabolism 
of LTC4 and LTD4 by PMNs compared with calcium ionophore. That study also 
indicated that inhibitors of oxidative burst decreased LTC4 metabolism. 
We also found that zafirlukast did not inhibit superoxide generation from the 
X-XOD system. This finding suggests that the antioxidant effect of zafirlukast 
does not originate from its ability to scavenge superoxide but rather from its 
capacity to inhibit ROS generation i PMNs. 
Based on the findings of the present study, we speculate that the activation 
of PMNs in patients with bronchial asthma results in increased generation of 
LTs, which, in turn, act on PMN cys LT1R to stimulate the release of ROSs. Our 
results uggest that zafirlukast interferes with this autocrine activation of PMNs 
by blocking the cys LT receptors, thereby inhibiting ROS production. 
Our findings might explain the mechanism of action of cys LTs in producing 
tissue inflammation and might indicate that LT receptor antagonists could, in 
addition to their use as anti-inflammatory drugs, be used as antioxidants. 
The present study had some limitations, including the small number of 
patients and the fact that they had mild to moderate stable asthma treated 
with f52-agonists as needed. In addition, this was an in vitro study. It would be 
interesting to study asthmatic patients during exacerbations of their disease 
and to perform in vivo measurements to determine whether the findings are 
confirmed. 
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CONCLUSIONS 
In this study of the effects of zafirlukast on PMNs in asthmatic patients and 
healthy controls, zafirlukast inhibited ROS production when PMNs were stimu- 
lated with PMA but not OPZ in asthmatic patients. In contrast, in healthy controls, 
zafirlukast inhibited ROS production by PMNs when stimulated with PMA or OPZ. 
Incubation of zafirlukast with PMNs for up to 1 hour inc teased its inhibitory effect 
on ROS production in healthy controls. The LT receptor antagonist zafirlukast 
had no scavenging effect on ROS generation in human isolated PMNs. 
ACKNOWLEDGMENTS 
AstraZeneca Pharmaceuticals LP, Macclesfield, United Kingdom, provided the 
zafirlukast. 
The authors thank Professor Abdel Galil Abdel Gader, PhD, FRCP, Depart- 
ment of Physiology, King Saud University, for reviewing the manuscript, and 
Casimero Victoria, BSMT, Neutrophil Function Laboratory, Department of Phys- 
iology, King Saud University, for technical assistance. 
REFERENCES 
1. Gern JE, Lemanske RF Jr, Busse WW. Early life origins of asthma. J Clin Invest. 
1999;104:837-843. 
2. Hanazawa T, Kharitonov SA, Barnes PJ. Increased nitrotyrosine in exhaled breath 
condensate of patients with asthma. Am JRespir Crit Care Med. 2000;162'. 1273-1276. 
3. Henson PM, Wenzel SE. Neutrophils and their mediators in asthma. In: Busse WW, 
Holgate ST, eds. Asthma and Rhinitis. 2nd ed. Oxford, United Kingdom'. Blackwell 
Science; 2000'.503-517. 
4. Surette ME, Krump E, Picard S, Borgeat P. Activation of leukotriene synthesis in 
human neutrophils by exogenous arachidonic acid'. Inhibition by adenosine A(2a) 
receptor agonists and crucial role of autocrine activation by leukotriene B(4). Mol 
Pharmacol. 1999;56:1055-1062. 
5. Hay DW, Torphy T J, Undem B J. Cysteinyl leukotrienes in asthma: Old mediators up 
to new tricks. Trends Pharmacol Sci. 1995;16:304-309. 
6. Menard G, Bissonnette EY. Priming of alveolar macrophages by leukotriene D(4): 
Potentiation of inflammation. Am J Respir Cell Mol Biol. 2000;23:572-577. 
7. Johnson HG, McNee ML, Secretogogue r sponses of leukotriene C4, D4: Comparison 
of potency in canine trachea in vivo. Prostaglandins. 1983;25:237-243. 
8. Marom Z, Shelhamer JH, Bach MK, et al. Slow-reacting substances, leukotrienes C4 
and D4, increase the release of mucus from human airways in vitro, Am Rev Respir 
Dis. 1982;126:449-451. 
9. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann 
Intern Med, 1997;127:472-480, 
10. Lockhart A, Dinh-Xuan AT. Physiopathology of asthma: What role for leukotrienes? 
[in French]. Rev Pneumol Clin. 1997;53:119-127. 
11. Left JA. Leukotriene modifiers as novel therapeutics in asthma. Clin Exp Allergy. 
1998;28(Suppl 5):147-153. 
291 
CURRENT THERAPEUTIC RESEARCH 
12. Weiss EB, BellinG JR. Leukotriene-associated toxic oxygen metabolites induce airway 
hyperreactivity, Chest. 1986;89:709-716, 
13. Lipworth BJ. The emerging role of leukotriene antagonists in asthma therapy. Chest. 
1999;115:313-316. 
14. Edelman JM, Turpin JA, Bronsky EA, et al, for the Exercise Study Group, Oral mon- 
telukast compared with inhaled salmeterol to prevent exercise-induced bronchocon- 
striction. A randomized, double-blind trial. Ann Intern Med. 2000;132:97-104. 
15. Calhoun WJ. Summary of clinical trials with zafirlukast. Am J Respir Crit Care Med. 
1998; 157(Suppl):S238-S246. 
16. Busse WW, McOill KA, Horwitz RJ. Leukotriene pathway inhibitors in asthma and 
chronic obstructive pulmonary disease. Clin Exp Allergy. 1999;29:110-115. 
17. Cakmak G, Demir T, Oemicioglu B, et al. The effects of add-on zafirlukast treatment 
to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic 
cationic protein and total antioxidant capacity in asthmatic patients. Tohoku J F, xp 
Med. 2004;204:249-256. 
18. Hasegawa H, Suzuki K, Nakaji S, Sugawara K. Analysis and assessment of the capac- 
ity of neutrophils to produce reactive oxygen species in a 96-well microplate format 
using lucigenin- and luminol-dependent chemiluminescence. J Immunol Methods. 
1997;210:1-10. 
19. Van Dyke K, Van Dyke C, Udeinya J, et al. A new screening system for nonsteroidal 
anti-inflammatory drugs based upon inhibition of chemiluminescence produced 
from human cells (granulocytes). Clin Chem. 1997;25:1655-1661. 
20. Gionchetti P, Guarnieri C, Campieri M, et al. Scavenger effect of sulfasalazine, 
5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci. 
1991;36:174-178. 
21. Braga PC, Dal Sasso M, Dal Negro R. Inhibitory effects of zafirlukast on respiratory 
bursts of human neutrophils. Drugs Exp Clin Res. 2002;28:133-145. 
22. Della Bianca V, Orzeskowiak M, Dusi S, Rossi F. Transmembrane signaling pathways 
involved in phagocytosis and associated activation of NADPH oxidase mediated by 
Fc gamma Rs in human neutrophils. JLeukoc Biol. 1993;53:427-438. 
23. Sala A, Folco G. Neutrophils, endothelial cells, and cysteinyl eukotrienes: A new 
approach to neutrophil-dependent i flammation? Biochem Biophys Res Commun. 
2001 ;283:1003-1006. 
24. Raulf M, Konig W. Modulation of leukotriene release from human polymorphonuclear 
leucocytes by PMA and arachidonic acid. Immunology. 1988;64:51-59. 
25. Werz O, Klemm J, Samuelsson B, Radmark O. Phorbol ester up-regulates capacities 
for nuclear translocation and phosphorylation 5-1ipoxygenase in Mono Mac 6 cells 
and human polymorphonuclear leukocytes. Blood. 2001;97:2487-2495. 
26. Kato M, Nakano M, Morikawa A, et al. Ability of polymorphonuclear leukocytes to 
generate active oxygen species in children with bronchial asthma. Use of chemilumi- 
nescence pro bes with a Cypridina luciferin analog and luminol. Int Arch Allergy Appl 
Immunol. 1991;95:17-22. 
27. Berends C, Hoekstra MO, Dijkhuizen B, et al. Expression of CD35 (CR1) and CDllb 
(CR3) on circulating neutrophils and eosinophils from allergic asthmatic hildren. 
Clin Exp Allergy. 1993;23:926-933, 
28. Di Oennaro A, Carnini C, Buccellati C, et al, Cysteinyl-leukotrienes r ceptor activa- 
tion in brain inflammatory eactions and cerebral edema formation: A role for trans- 
cellular biosynthesis of cysteinyl-leukotrienes, FASEB J. 2004;18:842-844, 
292 
H.A. AI-Zamil et  al. 
29. Steinke JW, Borish L. Leukotriene receptors in rhinitis and sinusitis. Curr Allergy 
Asthma Rep. 2004;4:217-223. 
30. Accomazzo MR, Rovati GE, Vigano T, et al. Leukotriene D4-induced activation of 
smooth-muscle c ils from human bronchi s partly Ca2+-independent, Am J Respir 
Crit Care Med. 2001;163:266-272. 
31. Figueroa D J, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1
receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit 
Care Med. 2001;163:226-233. 
32. Minoguchi K, Adachi M, Leukotriene modifiers [in Japanese], NipponRinsho, 2001;59: 
1979-1985. 
33. Bouchelouche PN, Berild D. Possible existence of leukotriene D4 receptors and 
mechanism of their signal transduction i human polymorphonuclear leukocytes. 
Scand J Clin Lab Invest Suppl. 1991;204:47-55. 
34. Baud L, Koo CH, Ooetzl E J. Specificity and cellular distribution of human polymor- 
phonuclear leucocyte receptors for leukotriene C4. Immunology. 1987;62:53-59. 
35. Raulf M, Stuning M, Konig W. Effect of cations on leukotriene release: Requirements 
for the metabolism of peptide-leukotrienes (l ukotrienes C4, D4) by human polymor- 
phonuclear granulocytes. Immunology. 1986;58:479-487. 
Address correspondence to: Hana A. AI-Zamil, MSc, Department of Physiology, 
College of Medicine, King Saud University, P.O. Box 52179, Riyadh 11563, Saudi 
Arabia. E-mail: hanazamil@yahoo.com 
293 
